Update on viral hepatitis in 2004

Current Opinion in Gastroenterology

Volumn 21, Issue 3, 2005, Pages 300-307

  Fung, Scott K ^a   Lok, Anna S F ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adefovir; Antiviral resistances; Hepatitis B; Hepatitis C; Lamivudine; Pegylated interferon

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CD4 ANTIGEN; CILUPREVIR; CIRCULAR DNA; CLEVUDINE; COVALENTLY CLOSED CIRCULAR DNA; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SERINE PROTEINASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ANTIVIRAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHRONIC HEPATITIS; COMORBIDITY; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DISEASE COURSE; DRUG SAFETY; GENOTYPE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VACCINATION; VIRUS HEPATITIS; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS C; HUMANS;

EID: 17844378198     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000158109.13722.36     Document Type: Review

References (58)

1. Liaw YF, Sung JJY, Chow WC, et al. Cirrhosis Asian Lamivudine Multicentre Study Group: Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med 2004; 351:1521-1531. This landmark article is the first major randomized study to provide strong evidence that nucleoside analogue agents can improve long-term liver-related outcomes in chronic HBV infection.
2. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39:804-810.
3. Chung RT, Andersen J, Volberding P, et al. ACTG A5071 Study Team: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
4. Shiftman ML, Di Bisceglie AM, Lindsay KL, et al. HALT-C Trial Group.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
5. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. APRICOT Study Group.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. One of the first major clinical studies to show that HIV-HCV coinfected patients respond well to combination therapy for HCV and that treatment of liver disease in this group of patients should be seriously considered.
6. Advisory Committee on Immunization Practices: Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Review 1999; 48:1-37.
7. Dato V, Weltman A, Waller K, et al. Hepatitis A outbreak associated with green onions at a restaurant: Monaca, Pennsylvania, 2003. JAMA 2003; 290:3187-3190.
8. Miller J, Finelli L, Bell BP. Incidence of acute hepatitis B: United States, 1990-2002. JAMA 2004; 291:416-447.
9. Hsu YS, Chien RN, Yeh CT, et al. Long term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527.
10. McMahon B, Holck P, Bulkow L, Snowball MM. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-768.
11. Manno M, Gamma C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127:756-763.
12. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
13. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus super-infection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024-1029.
14. Newbold J, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69:3350-3357.
15. Tuttleman J, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell 1986; 47: 451-460.
16. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
17. Di Marco V, Marzano A, Lampertico P, et al. Italian Association for the Study of the Liver Lamivudine Study Group I: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883-891.
18. Sanantonio T, Mazzola M, Iacovazzi T, et al. Long term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32:300-306.
19. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HBeAg-negative chronic hepatitis B [abstract]. J Hepatol 1999; 30:117.
20. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11:432-438.
21. Lok AS, Liang RHS, Chiu EKW, et al. Reactivation of hepatitis B virus patients receiving cytotoxic chemotherapy: report of a prospective study. Gastroenterology 1991; 100:182-188.
22. Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis virus reactivation in patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
23. Lau GKK, Yiu HHY, Fong DYT, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-1749.
24. Lau DT, Everhart JE, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-1667.
25. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-975.
26. Marcellin P, Mommeja-Marin H, Sacks S, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-148.
27. Cooksley WGE, Piratvisuth T, LeeSD, et al. Peginterferonalfa-2a(40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305.
28. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217. The first phase III trial to demonstrate the efficacy of pegylated interferon for the treatment of chronic hepatitis B. A longer treatment duration (>1 year) may be necessary to see a benefit from combination therapy.
29. Perrillo RP, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90.
30. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101. Data from this report justify the use of adefovir dipivoxil as salvage therapy for patients with confirmed genotypic resistance to lamivudine. Overlapping lamivudine with adefovir during the transition period may reduce lamivudine withdrawal flares in ALT.
31. Kuo A, Dienstag J, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2:266-272.
32. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36:507-508.
33. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-1425.
34. Yu MW, Bartosch B, Zhang P, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV positive plasma. Proc Natl Acad Sci U S A 2004; 101:7705-7710.
35. Knodeli RG, Conrad ME, Ginsberg AL, et al. Efficacy of gamma-globulin in preventing non-A non-B post-transfusion hepatitis. Lancet 1976; 1: 557-561.
36. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
37. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88.
38. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39:1213-1219.
39. Hofer H, Watkins-Riedei T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37:60-64.
40. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88.
41. Wiegand J, Jackel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40:98-107.
42. Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8:264-269.
43. Reddy KR, Hoofnagle J, Tong M, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 787-793.
44. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
45. Jeffers U, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-1708.
46. Fried M, Shiftman M, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:982.
47. Manns M, McHutchinson J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:965.
48. Hadziyannis S, Seite H, Morgan TR, et al. PEGASYS International Study Group: Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355. This large clinical trial provides quality evidence for tailoring HCV therapy according to genotype. It will change clinical practice by reducing the duration of therapy and dose of ribavirin for patients with genotype 2 or 3, thus reducing adverse effects of treatment.
49. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
50. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
51. Lessens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179:1254-1258.
52. Brau N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17:2279-2290.
53. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426:186-189.
54. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127:1347-1355. A pilot study, this paper represents a new class of oral antiviral agent, serine protease inhibitors, for the treatment of chronic HCV infection. Reports of cardiotoxicity in animals may ultimately limit further development of this agent in humans, although other agents in this class show promise.
55. Farci P, Mandas A, Coiana A, eti al. Treatment of chronic hepatitis D with interferon alpha-2a. N Engl J Med 1994; 330:88-94.
56. Lau DT, Kleiner DE, Park Y, et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117:1229-1233.
57. Rosina F, Pintus C Meshievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13:1052-1056.
58. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alfa therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740-1749. One of the first reports to document long-term benefits of interferon treatment in HBV-HDV coinfection.